Align Technology, Inc. $ALGN Shares Sold by Logan Capital Management Inc.

Logan Capital Management Inc. reduced its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 23.3% during the 1st quarter, HoldingsChannel reports. The firm owned 6,430 shares of the medical equipment provider’s stock after selling 1,952 shares during the quarter. Logan Capital Management Inc.’s holdings in Align Technology were worth $1,021,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ALGN. Redmond Asset Management LLC lifted its stake in Align Technology by 2.0% during the first quarter. Redmond Asset Management LLC now owns 2,769 shares of the medical equipment provider’s stock worth $440,000 after purchasing an additional 54 shares in the last quarter. Horizon Investments LLC increased its holdings in Align Technology by 6.2% in the first quarter. Horizon Investments LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $162,000 after buying an additional 59 shares during the last quarter. Washington Trust Advisors Inc. increased its holdings in Align Technology by 5.2% in the first quarter. Washington Trust Advisors Inc. now owns 1,205 shares of the medical equipment provider’s stock valued at $191,000 after buying an additional 60 shares during the last quarter. Fulcrum Capital LLC boosted its stake in Align Technology by 0.8% in the first quarter. Fulcrum Capital LLC now owns 9,282 shares of the medical equipment provider’s stock valued at $1,475,000 after acquiring an additional 70 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of Align Technology by 18.8% during the first quarter. Covestor Ltd now owns 493 shares of the medical equipment provider’s stock worth $78,000 after buying an additional 78 shares during the period. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Align Technology Stock Down 0.7%

Align Technology stock opened at $135.93 on Wednesday. The firm has a 50-day moving average price of $164.43 and a two-hundred day moving average price of $171.20. The firm has a market capitalization of $9.85 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 1.54 and a beta of 1.65. Align Technology, Inc. has a 52-week low of $127.70 and a 52-week high of $262.87.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. Research analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology declared that its board has initiated a share repurchase plan on Tuesday, August 5th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the medical equipment provider to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Morgan Stanley restated an “equal weight” rating and issued a $154.00 price objective (down previously from $249.00) on shares of Align Technology in a research report on Thursday, July 31st. Evercore ISI lifted their target price on shares of Align Technology from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. Zacks Research lowered shares of Align Technology from a “hold” rating to a “strong sell” rating in a report on Monday, September 1st. Stifel Nicolaus reduced their target price on shares of Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a report on Thursday, July 31st. Finally, Mizuho set a $210.00 price target on shares of Align Technology in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Align Technology currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.00.

Insider Transactions at Align Technology

In other news, CEO Joseph M. Hogan bought 7,576 shares of Align Technology stock in a transaction on Friday, August 1st. The stock was purchased at an average cost of $131.49 per share, with a total value of $996,168.24. Following the purchase, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.66% of the stock is owned by insiders.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.